Start here if you're new
what it is
GSK makes prescription drugs and vaccines, then lives or dies by whether regulators, doctors, and patients keep saying yes.
how it gets paid
Last year Gsk made $41.9B in revenue.
what just happened
GSK reported $0.68 EPS versus a $0.64 estimate, a small beat that still matters with the stock already up 18%.
At a glance
A+ balance sheet — rock-solid finances — built to survive anything
45/100 earnings predictability — expect surprises
13.0% return on capital — nothing to write home about
xvary composite: 76/100 — average
$43B fy2028 rev est
What they do
GSK makes prescription drugs and vaccines, then lives or dies by whether regulators, doctors, and patients keep saying yes.
GSK wins the boring way. It converts sales into a 27.0% operating margin and posts a 13.0% return on capital (money earned on money invested), so what: the business still throws off solid profits after heavy drug spending. Its beta is 0.65, which means the stock has swung less than the market, so you get a steadier pharma name when headlines get weird.
How they make money
$41.9B
annual revenue
total revenue
$41.9B
n/a
The products that matter
hiv, respiratory, immunology, oncology drugs
Specialty Medicines
$18.8B · 45% of revenue
This is the biggest segment at $18.8B, and it grew 10%. If you are looking for the growth engine, this is it.
main growth engine
preventive immunizations
Vaccines
$12.6B · £9.2B reported
Vaccines generated $12.6B, while Shingrix alone contributed £3.6B and grew 8%. This segment is the cash-flow anchor, but it now has to defend itself against competition and policy noise.
cash-flow anchor
legacy primary-care portfolio
General Medicines
$10.5B · -2% growth
It is still a $10.5B business, but sales fell 2%. That makes it the funding base, not the future.
legacy base
Key numbers
$20.0B
long-term debt
Long-term debt → money owed over many years → so what: it is 16% of capital, which looks manageable next to an A+ balance sheet grade.
27.0%
operating margin
Operating margin → profit after running the business → so what: GSK keeps $0.27 from each $1 of sales before interest and taxes.
13.0%
return on capital
Return on capital → profit earned on invested money → so what: GSK earns $0.13 for every $1 tied up in the business.
0.65
beta
Beta → how jumpy the stock is versus the market → so what: GSK has been calmer than the average stock.
Financial health
A+
strength
- balance sheet grade A+ — near the highest rating possible
- risk rank 1 — safer than 95% of stocks
- price stability 90 / 100
- long-term debt $20.0B (16% of capital)
- net profit margin 14.4% — keeps 14 cents of every dollar in revenue
- return on equity 28% — $0.28 profit for every $1 investors have put in
A+ with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in GSK 3 years ago → it's now worth $15,550.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
GSK reported $0.68 EPS versus a $0.64 estimate, a small beat that still matters with the stock already up 18%.
Consensus shows a +6.25% EPS surprise. Revenue was not provided in the data here, while prior company commentary pointed to better-than-expected third-quarter sales and a stronger 2025 setup.
$0.68
reported eps
$0.64
est. eps
6.25%
surprise
the number that mattered
The key number is the $0.04 EPS beat, because even modest beats get judged harder when the stock already trades above the $47 base case.
-
the price of gsk’s adrs has risen a whopping 18% since our lateseptember report.this is a huge move for an adr that has a beta of only.65 and a growth consistency rating of 10 (out of 100).
-
the move came after the drug giant delivered better-than-expected third-quarter sales, and stated that 2025 sales would be up 6%-8%.the magnitude of the rise, however, was surprising, given that gsk received mixed news regarding a highly anticipated fda decision about its new blood cancer treatment blenrep.
-
the fda approved the drug for only one of the two indications for which it applied.
-
side effects appeared to be the sticking point.gsk will have to go back to the drawing board in order to get the second indication approved, hopefully by mid-2026.
-
meanwhile, trading volume has been higher than normal.certainly, the rosier outlook has spurred investment advisers into encouraging their clients to buy more, but we also think that investors are seeking more safety in the drug realm. gsk has traditionally been seen by conservative investors as one of the more financially secure adrs, with a risk rank of 1 (highest) and a balance sheet grade rating of a+. in addition, income-oriented investors have been attracted to the adr’s consistently above-average dividend yield.
source: Yahoo Finance consensus, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is Zantac-related litigation and disclosure claims. This is a pharma stock with a defensive multiple and a very non-defensive legal overhang.
med
Zantac litigation
A pending securities fraud class action alleges GSK knew about a carcinogen risk tied to Zantac for decades. Even when cash damages are hard to handicap, headline risk is easy to see.
The immediate issue is not just legal cost. It is the possibility that a stock bought for stability stops trading like one.
med
vaccine competition
Vaccines produced $12.6B in revenue, and Arexvy now faces direct RSV competition from Pfizer's Abrysvo. When a cash engine gets more crowded, the rest of the portfolio has to work harder.
Pressure here matters because vaccines are still one of the funding sources for GSK's oncology buildout.
med
Shingrix normalization
Shingrix generated £3.6B and grew 8%, but catch-up vaccination waves do not last forever. If that growth cools, a lot of the easy vaccine optimism cools with it.
One product at £3.6B is big enough to move the group result on its own.
med
oncology execution
Oncology grew 43% to £2B, but £2B is still small next to a £32.7B company. The market will need more than early momentum if management wants a higher valuation multiple.
Missing on pivotal trial timing, additional FDA approvals, or commercial uptake would leave GSK looking like a slow-growth incumbent again.
Vaccines are a $12.6B business and Shingrix alone is £3.6B, while oncology is only £2B today. That means the mature portfolio still has to fund and protect the transformation.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings report
Estimated for Wednesday, April 29, 2026. You want to see whether Specialty Medicines keeps outgrowing the rest of the company.
legal
Zantac case headlines
This stock is priced like a stable pharma name. Legal surprises are the cleanest way to break that setup.
metric
Shingrix growth
Shingrix did £3.6B and grew 8%. If that starts fading fast, one of GSK's easiest growth supports fades with it.
pipeline
2026 oncology cadence
Management expects 10 pivotal trial starts in 2026. That is the operating proof behind the transformation story.
Analyst rankings
earnings predictability
45 / 100
This is below average predictability. In human-speak, analysts do not view GSK as a clean, autopilot earnings story.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 410 buyers vs. 373 sellers in 3q2025. total institutional holdings: 0.4B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$35
$58
$49
current price
$47
target midpoint · 5% from current · 3-5yr high: $60 (+20% · 8% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive